title: Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.
abstract: Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy.
authors.affiliation: Walter Reed Medical Center, Bethesda, Md., USA.
authors.forename: Corey A
authors.initials: CA
authors.lastname: Carter
authors.affiliation: EpicentRx, Inc., Mountain View, Calif., USA.
authors.forename: Bryan
authors.initials: B
authors.lastname: Oronsky
authors.affiliation: EpicentRx, Inc., Mountain View, Calif., USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Caroen
authors.affiliation: EpicentRx, Inc., Mountain View, Calif., USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Scicinski
authors.affiliation: Walter Reed Medical Center, Bethesda, Md., USA.
authors.forename: Aiste
authors.initials: A
authors.lastname: Degesys
authors.affiliation: Department of Bioengineering, University of California, La Jolla, Calif., USA.
authors.forename: Pedro
authors.initials: P
authors.lastname: Cabrales
authors.affiliation: Moores Cancer Center, La Jolla, Calif., USA.
authors.forename: Tony R
authors.initials: TR
authors.lastname: Reid
authors.affiliation: Walter Reed Medical Center, Bethesda, Md., USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Brzezniak
keywords: Partial response; Platinum doublets; RRx-001; Refractory small-cell lung cancer